Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Other Operating Expenses (2020 - 2022)

Immunocore Holdings' Other Operating Expenses history spans 3 years, with the latest figure at -$1172.9 for Q4 2022.

  • On a quarterly basis, Other Operating Expenses fell 101.24% to -$1172.9 in Q4 2022 year-over-year; TTM through Sep 2023 was -$1172.9, a 101.23% decrease, with the full-year FY2021 number at -$77000.0, down 153.5% from a year prior.
  • Other Operating Expenses hit -$1172.9 in Q4 2022 for Immunocore Holdings, down from $1341.8 in the prior quarter.
  • Over the last five years, Other Operating Expenses for IMCR hit a ceiling of $429626.7 in Q2 2020 and a floor of -$113000.0 in Q1 2021.
  • Historically, Other Operating Expenses has averaged $52219.5 across 3 years, with a median of $13011.6 in 2020.
  • The widest YoY moves for Other Operating Expenses: up 614.61% in 2021, down 981.53% in 2021.
  • Tracing IMCR's Other Operating Expenses over 3 years: stood at $13204.5 in 2020, then surged by 614.61% to $94360.7 in 2021, then plummeted by 101.24% to -$1172.9 in 2022.
  • Business Quant data shows Other Operating Expenses for IMCR at -$1172.9 in Q4 2022, $1341.8 in Q1 2022, and $94360.7 in Q4 2021.